Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 19

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 19
---
17D -16D -15D -14D -13D -12D -11D -10D High Myopia ~10x less prevalent than moderate and low myopia Source: 2024 Market Scope Refractive Error Model. Note: High myopia is generally classified as a refractive error above -6D, moderate myopia is between -6D to -3D and low myopia between -3D to -0.5D on the diopter curve. A Diopter is a Unit Of Measurement of the Refractive Power of a Lens -8D -7D -6D -5D -4D -3D -9D Moderate & Low Myopia ~10x the size of high myopia -9.8D STAAR’S GLOBAL AVERAGE DIOPTER, FY20 -9.4D STAAR’S GLOBAL AVERAGE DIOPTER, FY24 In the last four years, STAAR has made little progress expanding beyond high myopia Alcon’s size and scale should enable EVO ICL to reach its full potential below high myopia patients. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR competes with large, well resourced, global companies that offer numerous treatment options for myopia ($ in billions) Select Competitive Players ’24A Net Sales $0.3 $28 $5(1) $10 $5 $2 $4 $5 Optometrist P P P P P P P Ophthalmologist P P P P P Eyeglasses P P P Contact Lenses P P P P Myopia Progression(2) P P P P P Laser Vision Correction P P P P Phakic IOL P P P Non-Surgical Surgical Channel (4) STAAR faces significant competition from multiple myopia treatments, more typically used for mid/lower diopter patients Source: Company filings. (1) Vision Net Sales only. (2) Inclusive of glasses and contact lenses. (3) Via distribution agreement with Ophtec. (4) Via Wuxi partnership. (3) EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS EssilorLuxottica

STAAR has taken steps to mitigate short-term tariff risk in China, but medium and longer-term risk remain significant Although STAAR’s cons